Virologic response in patients with chronic hepatitis C after treatment with interferon 2b alone or in combination with ribavirin.

被引：0
|
作者：
Futuh, ARA
Solayman, AEM
El Hendawy, SM
El Hadad, SM
Omar, MM
Kamel, MM
机构：
[1] Mansoura Int Hosp, Mansoura, Egypt
[2] Asuit Univ, Asuit, Egypt
[3] Univ Mansoura, Mansoura, Egypt
[4] Ein Shams Univ, Cairo, Egypt
[5] Theodor Bilharse Res Inst, Cairo, Egypt
[6] Ein Shams Univ, Cairo, Egypt
来源：
HEPATOLOGY | 2002年 / 36卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1706
引用
收藏
页码：589A / 589A
页数：1
相关论文
共 50 条
  • [1] Durability of sustained virologic response in patients with chronic hepatitis C after treatment with interferon α-2b alone or in combination with ribavirin.
    McHutchison, JG
    Davis, GL
    Esteban-Mur, R
    Poynard, T
    Ling, MH
    Garaud, JJ
    Albrecht, J
    HEPATOLOGY, 2001, 34 (04) : 244A - 244A
  • [2] Interferon Alpha 2b in Combination with Ribavirin as a Treatment for Chronic Hepatitis C
    Mandokhel, Sherbet Khan
    Aziz-U-Rehman
    Khan, Mohammad Saleem
    Azeemullah
    PAKISTAN JOURNAL OF MEDICAL & HEALTH SCIENCES, 2011, 5 (01): : 168 - 171
  • [3] Interferon-α2b/ribavirin (REBETRON®) treatment for chronic hepatitis C -: Population pharmacokinetics and pharmacodynamics of ribavirin.
    Glue, P
    Jen, F
    Gupta, SK
    Lau, G
    HEPATOLOGY, 1999, 30 (04) : 190A - 190A
  • [4] Daily or three times per week interferon α-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C not responding to previous interferon alone
    de Lédinghen, V
    Trimoulet, P
    Winnock, M
    Bernard, PH
    Bourlière, M
    Portal, I
    Rémy, AJ
    Szostak, N
    Lévy, S
    Tran, A
    Abergel, A
    Chêne, G
    Fleury, H
    Couzigou, P
    JOURNAL OF HEPATOLOGY, 2002, 36 (06) : 819 - 826
  • [5] Sustained response in chronic hepatitis C patients after six months of interferon or interferon and ribavirin.
    Cheinquer, H
    Coelho-Borges, S
    Cheinquer, N
    Lunge, V
    Ikuta, N
    Fonseca, A
    HEPATOLOGY, 1998, 28 (04) : 477A - 477A
  • [6] Treatment of chronic hepatitis C with PEGylated interferon and ribavirin.
    Cornberg M.
    Wedemeyer H.
    Manns M.P.
    Current Gastroenterology Reports, 2002, 4 (1) : 23 - 30
  • [7] Prospective study on early virologic response to treatment with interferon α-2b plus ribavirin in patients with chronic hepatitis C genotype 1b
    Nagaki, M
    Imose, M
    Naiki, T
    Kimura, K
    Hayashi, H
    Shimizu, M
    Ohnishi, H
    Tomita, E
    Sugihara, J
    Amano, K
    Sakai, T
    Kojima, T
    Katsumura, N
    Kondo, Y
    Fujmoto, M
    Moriwaki, H
    HEPATOLOGY RESEARCH, 2005, 33 (04) : 285 - 291
  • [8] Efficacy of high dose consensus interferon for the treatment of chronic hepatitis C non responders to interferon alpha 2b and ribavirin.
    Moskovitz, DN
    Manoharan, P
    Heathcote, J
    HEPATOLOGY, 2001, 34 (04) : 577A - 577A
  • [9] Early virologic response value as predictive factor of sustained virologic response to treatment with interferon α-2b plus ribavirin in chronic hepatitis C patients with or without HIV coinfection
    Buenestado-Garcia, Juan
    Rubio-Rivas, Manuel
    Rene-Espinet, Josep Maria
    Pinol-Felis, Carmen
    Egido-Garcia, Ramon
    Rubio-Caballero, Manuel
    MEDICINA CLINICA, 2006, 127 (15): : 561 - 566
  • [10] Viusid, a nutritional supplement, in combination with interferon α-2b and ribavirin in patients with chronic hepatitis C
    Gomez, Eduardo Vilar
    Oramas, Bienvenido Gra
    Soler, EnriqueArus
    Navarro, Raimundo Llanio
    Domech, Caridad Ruenes
    LIVER INTERNATIONAL, 2007, 27 (02) : 247 - 259
12345